Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
REGULATORY
MOF Panel Pushes for Full Drug Price Revision in FY2027: Budget Proposal
Japan’s Fiscal System Council on November 20 submitted its budget recommendation for FY2027 to Finance Minister Satsuki Katayama, renewing its call for a full-scale off-year drug price revision next April and a more selective approach to innovation incentives. The so-called…
To read the full story
Related Article
- MOF Presses for Full FY2027 Drug Price Revision Without Price Gap Thresholds
November 4, 2026
- Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
October 5, 2026
- MOF Panel Renews Push for Full-Scale Off-Year Revision in FY2027
June 29, 2026
- MOF Panel Submits Budget Proposal, Urges Wider CEA Use and More Frequent Re-Pricing
December 3, 2025
REGULATORY
- MOF Panel Pushes for Full Drug Price Revision in FY2027: Budget Proposal
November 20, 2026
- Mumps Shots Gain Strong Backing as Japan Weighs FY2027 NIP Priorities
November 20, 2026
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- Pharma Prods LDP to Rethink CEA Expansion, Project Team to Compile Proposal
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026





